CYTOKINETICS INC
NASDAQ: CYTK (Cytokinetics, Incorporated)
Last update: 22 hours ago54.09
-1.84 (-3.29%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Cytokinetics, Incorporated | Bearish | Bullish |
Stockmoo Score
|
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2024 | 4,575,558 |
| Vestal Point Capital, Lp | 30 Jun 2024 | 2,075,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (HC Wainwright & Co., 66.39%) | Buy |
| Median | 72.00 (33.11%) | |
| Low | 60.00 (Goldman Sachs, 10.93%) | Hold |
| Average | 74.20 (37.18%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 55.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 05 Sep 2024 | 71.00 (31.26%) | Buy | 55.93 |
| 24 Jun 2024 | 65.00 (20.17%) | Buy | 53.90 | |
| JMP Securities | 04 Sep 2024 | 78.00 (44.20%) | Buy | 54.89 |
| HC Wainwright & Co. | 03 Sep 2024 | 90.00 (66.39%) | Buy | 54.56 |
| 12 Aug 2024 | 90.00 (66.39%) | Buy | 56.18 | |
| Needham | 03 Sep 2024 | 72.00 (33.11%) | Buy | 54.56 |
| 09 Aug 2024 | 72.00 (33.11%) | Buy | 55.79 | |
| Goldman Sachs | 13 Aug 2024 | 60.00 (10.93%) | Hold | 56.07 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PARSHALL B LYNNE | - | 57.07 | -5,000 | -285,350 |
| Aggregate Net Quantity | -5,000 | |||
| Aggregate Net Value ($) | -285,350 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 57.07 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PARSHALL B LYNNE | Director | 26 Aug 2024 | Sell (-) | 5,000 | 57.07 | 285,350 |
| PARSHALL B LYNNE | Director | 26 Aug 2024 | Option execute | 5,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |